Department of Pharmacy, Pharmacotechnology Documentation & Transfer Unit, Preclinical & Translational Pharmacology, Health & Nutritional Sciences, University of Calabria, Rende, 87036, Italy.
Regional Center for Serious Brain Injuries, S. Anna Institute, Crotone, 88900, Italy.
Pain Manag. 2022 Nov;12(8):879-885. doi: 10.2217/pmt-2022-0054. Epub 2022 Oct 3.
Migraine is the leading cause of years lived with disability in people under 50 and its burden is increased by calcitonin gene-related peptide (CGRP)-driven chronicity. Newly approved small molecules that antagonize the CGRP receptor, gepants, have advanced from the hepatotoxic first-generation telcagepant to third-generation intranasal zavegepant; during this process of drug development, rimegepant, ubrogepant and atogepant, which are orally administered, have been launched and approved for clinical use with no warning for hepatotoxicity. Real-world, long-term postmarketing data about the efficacy and safety of gepants are awaited. The aim of the present drug evaluation study was to provide an overview of the novel, third-generation intranasal zavegepant, encompassing its development and future perspectives.
偏头痛是 50 岁以下人群残疾年数的主要原因，降钙素基因相关肽 (CGRP) 驱动的慢性疾病会增加其负担。新批准的拮抗 CGRP 受体的小分子药物已从第一代具有肝毒性的 telcagepant 发展到第三代鼻内 zavegepant；在药物开发过程中，已上市并批准用于临床的口服 rimegepant、ubrogepant 和 atogepant 没有肝毒性警告。目前正在等待关于 gepants 的真实世界、长期上市后疗效和安全性的数据。本药物评估研究的目的是概述新型第三代鼻内 zavegepant，包括其开发和未来前景。
